Horus Pharma Group Launches Nordic Subsidiary

Horus Pharma, an independent French laboratory specializing in ophthalmology, has opened of a new subsidiary. From its base in Stockholm, Sweden, Horus Pharma Nordic will cover Sweden, Norway, Finland and Denmark.

Horus Pharma develops, patents and markets preservative-free eye and eyelid care products and solutions. Horus Pharma is headquartered in Nice, France and currently has a presence in Spain, the Benelux and Switzerland.

“I am proud of our steady growth and the expansion of our presence in Europe, which now also includes the Nordic countries. After two decades of pioneering the successful development and marketing of ranges of innovative products in various European countries, we are ready to play a critical role in helping ophthalmologists and their patients in the Nordic countries solve eye care challenges by offering them top-quality solutions," Claude Claret, CEO and co-founder of Horus Pharma, said in a company news release. "We are delighted to welcome Johan Marlowe as General Manager of the subsidiary. He brings 30 years of unique experience in ophthalmology and a deep knowledge of the Nordic market”.

“Horus Pharma will start acting as the local representative for Iluvien, indicated for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies, and the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye)," Johan Marlowe, General Manager Horus Pharma Nordic, said in a news release. "The product has been available on the French market since 2018 and was successfully launched in the Benelux in 2020.”

During the coming year Horus Pharma’s full range of products, which includes medical devices for treating glaucoma, allergies, inflammation, dry eye, and surgical and peri-surgical solutions as well as cosmetic products for eyelid hygiene, will progressively become available on the Nordic market.